Immunity Duration of a Recombinant Adenovirus Type-5 Vector-Based Ebola Vaccine and a Homologous Prime-Boost Immunisation in Healthy Adults in China: Final Report of a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial
The Lancet Global Health - United Kingdom
doi 10.1016/s2214-109x(16)30367-9
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 1, 2017
Authors
Publisher
Elsevier BV